Focused Ultrasound Enhances Central Nervous System Delivery of Bevacizumab for Malignant Glioma Treatment

Published Online:https://doi.org/10.1148/radiol.2016152444

This study provides evidence that using focused ultrasound–induced blood-brain barrier opening with MR imaging monitoring can enhance central nervous system monoclonal antibody delivery and suggests that focused ultrasound combined with bevacizumab is a promising anti–glioblastoma multiforme strategy.

Purpose

To demonstrate that magnetic resonance (MR) imaging–monitored transcranial focused ultrasound can enhance the delivery of the antiangiogenic monoclonal antibody bevacizumab into the central nervous system (CNS) for glioblastoma multiforme (GBM) treatment.

Materials and Methods

All animal experiments were approved by the animal committee and adhered to experimental animal care guidelines. Transcranial focused ultrasound exposure in the presence of microbubbles was used to open the blood-brain barrier (BBB) to enhance bevacizumab penetration into the CNS in healthy and glioma-bearing mice. Bevacizumab concentration was quantitated with high-performance liquid chromatography, and Western blot testing was performed to confirm the specific biologic form in the CNS. Penetration of bevacizumab into brain tissue was estimated in vivo by means of contrast material–enhanced MR imaging and quantitative gallium 68 (68Ga)-bevacizumab micro–positron emission tomography, and glioma progression was longitudinally followed with T2-weighted MR imaging. Hematoxylin-eosin staining and cluster of differentiation 31 immunostaining were used to assess morphologic changes and vascular inhibition at histologic examination. The two-tailed Student t test and the Mantel-Cox log-rank test were used for statistical analyses, with a significance level of .05.

Results

Focused ultrasound significantly enhanced bevacizumab penetration into the CNS by 5.7- to 56.7-fold compared with that in nonexposed brain (both P < .0001). Contrast-enhanced MR imaging indexes correlated with bevacizumab concentration (r = 0.748–0.857) in vivo. Focused ultrasound–enhanced bevacizumab delivery significantly retarded glioma progression, with a significantly increased median survival (median increase in survival time = 135% in the group treated with bevacizumab and focused ultrasound, P < .0001; as compared with 48% in the group treated with bevacizumab alone, P = .0002).

Conclusion

Focused ultrasound–enhanced bevacizumab delivery can provide an antivascularization normalization effect to suppress glioma.

© RSNA, 2016

Online supplemental material is available for this article.

References

  • 1. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. Lancet 2012;379(9830):1984–1996. Crossref, MedlineGoogle Scholar
  • 2. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3(1):24–40. Crossref, MedlineGoogle Scholar
  • 3. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009;5(11):610–620. Crossref, MedlineGoogle Scholar
  • 4. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359(6398):843–845. Crossref, MedlineGoogle Scholar
  • 5. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28):4733–4740. Crossref, MedlineGoogle Scholar
  • 6. Taylor J, Gerstner ER. Anti-angiogenic therapy in high-grade glioma (treatment and toxicity). Curr Treat Options Neurol 2013;15(3):328–337. Crossref, MedlineGoogle Scholar
  • 7. Hynynen K, McDannold N, Sheikov NA, Jolesz FA, Vykhodtseva N. Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage 2005;24(1):12–20. Crossref, MedlineGoogle Scholar
  • 8. Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 2001;220(3):640–646. LinkGoogle Scholar
  • 9. White PJ, Clement GT, Hynynen K. Longitudinal and shear mode ultrasound propagation in human skull bone. Ultrasound Med Biol 2006;32(7):1085–1096. Crossref, MedlineGoogle Scholar
  • 10. Liu HL, Hua MY, Chen PY, et al. Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology 2010;255(2):415–425. LinkGoogle Scholar
  • 11. Liu HL, Huang CY, Chen JY, Wang HY, Chen PY, Wei KC. Pharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment. PLoS One 2014;9(12):e114311. Crossref, MedlineGoogle Scholar
  • 12. Wei KC, Chu PC, Wang HY, et al. Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study. PLoS One 2013;8(3):e58995. Crossref, MedlineGoogle Scholar
  • 13. Aryal M, Vykhodtseva N, Zhang YZ, McDannold N. Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study. J Control Release 2015;204:60–69. Crossref, MedlineGoogle Scholar
  • 14. Treat LH, McDannold N, Zhang Y, Vykhodtseva N, Hynynen K. Improved anti-tumor effect of liposomal doxorubicin after targeted blood-brain barrier disruption by MRI-guided focused ultrasound in rat glioma. Ultrasound Med Biol 2012;38(10):1716–1725. Crossref, MedlineGoogle Scholar
  • 15. Kinoshita M, McDannold N, Jolesz FA, Hynynen K. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci U S A 2006;103(31):11719–11723. Crossref, MedlineGoogle Scholar
  • 16. Chu PC, Chai WY, Hsieh HY, et al. Pharmacodynamic analysis of magnetic resonance imaging-monitored focused ultrasound-induced blood-brain barrier opening for drug delivery to brain tumors. BioMed Res Int 2013;2013:627496. Crossref, MedlineGoogle Scholar
  • 17. Chai WY, Chu PC, Tsai MY, et al. Magnetic-resonance imaging for kinetic analysis of permeability changes during focused ultrasound-induced blood-brain barrier opening and brain drug delivery. J Control Release 2014;192:1–9. Crossref, MedlineGoogle Scholar
  • 18. Pardridge WM. Drug and gene delivery to the brain: the vascular route. Neuron 2002;36(4):555–558. Crossref, MedlineGoogle Scholar
  • 19. Rapoport SI. Blood-brain barrier in physiology and medicine. New York, NY: Raven, 1976. Google Scholar
  • 20. Ewing JR, Brown SL, Lu M, et al. Model selection in magnetic resonance imaging measurements of vascular permeability: Gadomer in a 9L model of rat cerebral tumor. J Cereb Blood Flow Metab 2006;26(3):310–320. Crossref, MedlineGoogle Scholar
  • 21. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000;2(4):306–314. Crossref, MedlineGoogle Scholar
  • 22. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001;61(18):6624–6628. MedlineGoogle Scholar
  • 23. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13(4):1253–1259. Crossref, MedlineGoogle Scholar
  • 24. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27(5):740–745. Crossref, MedlineGoogle Scholar
  • 25. Chinot OL, de La Motte Rouge T, Moore N, et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 2011;28(4):334–340. Crossref, MedlineGoogle Scholar
  • 26. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370(8):709–722. Crossref, MedlineGoogle Scholar
  • 27. O’Reilly MA, Hynynen K. Blood-brain barrier: real-time feedback-controlled focused ultrasound disruption by using an acoustic emissions-based controller. Radiology 2012;263(1):96–106. LinkGoogle Scholar
  • 28. Arvanitis CD, Livingstone MS, Vykhodtseva N, McDannold N. Controlled ultrasound-induced blood-brain barrier disruption using passive acoustic emissions monitoring. PLoS One 2012;7(9):e45783. Crossref, MedlineGoogle Scholar

Article History

Received November 26, 2015; revision requested January 20, 2016; revision received February 5; accepted February 15; final version accepted February 22.
Published online: May 18 2016
Published in print: Oct 2016